Business
FDA Center for Veterinary Medicine Grants Innocan a Fee Waiver in 2026 for the Third Consecutive Time
Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year.
About this update from Innocan Pharma Corporation
[{"type":"text","content":"HERZLIYA, Israel and CALGARY, AB, Feb. 27, 2026 /PRNewswire/ -- Innocan Pharma Corporation (CSE: INNO) (FSE: IP40) (OTCQB: INNPD) ("Innocan" or the "Company"), a pioneer in the pharmaceutical and biotechnology industries, is pleased to announce that the FDA's Center for Veterinary Medicine (CVM) has granted the Company a sponsor fee waiver for its LPT-CBD (Liposome Platform Technology-Cannabidiol) product for the third consecutive year.","length":469,"tagName":"p"},{"type":"image","alt":"Innocan Pharma Corporation Logo","displaySize":"","headline":null,"caption":"Innocan Pharma Corporation Logo","className":"","disableSlideshowImg":false,"size":{"original":{"width":400,"height":283,"url":"https://media.zenfs.com/en/prnewswire.com/7706f970d25ba77672f989a1db7cd166"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/oPW3SkEwNtEfwC86CS51RA--/YXBwaWQ9aGlnaGxhbmRlcjt3PTcwNTtoPTQ5OTtjZj13ZWJw/https://media.zenfs.com/en/prnewswire.com/7706f970d25ba77672f989a1db7cd166","width":400,"height":283}}},{"type":"text","content":"The FDA's Center for Veterinary Medicine (CVM) assesses annual fees for animal drug applications. Sponsors developing innovative products may request a fee waiver each year under the "significant barrier to innovation" provision. Accordingly, every year Innocan submits an annual renewal request that includes a brief update on development progress and forward plans. Following review of the Company's latest submission, CVM has again granted Innocan a fee waiver for the year 2026. This represents the Company's third consecutive annual waiver, underscoring CVM's continued recognition of Innocan's innovation-driven animal health program.","length":670,"tagName":"p"},{"type":"text","content":"The waiver relates to the Company's Liposomal Technology–CBD (LPT-CBD) drug product candidate, being developed as a subcutaneous injection for the management of chronic pain in dogs. In a blinded, crossover study conducted on osteoarthritic dogs, LPT-CBD demonstrated a statistically significant reduction in pain and meaningful improvements in overall well-being compared with placebo (empty liposomes) (1). Together with additional studies previously conducted in osteoarthritic dogs, these results provide robust evidence supporting LPT-CBD's analgesic potential and its su...